|Articles|March 19, 2020
Oncology Product Manufacturing in a Nondedicated Facility
Author(s)Baxter BioPharma Solutions
- Advantages of manufacturing immuno-oncology therapies in multiproduct facilities - Preventing cross-contamination and proper cleaning validation
Related Content
Sponsored Content
Trending on Pharmaceutical Technology
1
PharmTech Weekly Roundup–July 10, 2026
2
The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma
3
The FDA Moves to Modernize Drug Manufacturing Registration
4
What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline
5